The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy

Bibliography

• Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
   Google Scholar
• Lima A, Monteiro J, Bernardes M, et al. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. Biomed Res Int. 2014; 2014:368681.
   PubMed Web of Science ®Google Scholar
• Chaabane S, Marzouk S, Akrout R, et al. Genetic determinants of methotrexate toxicity in Tunisian patients with rheumatoid arthritis: a study of polymorphisms involved in the MTX metabolic pathway. Eur J Drug Metab Pharmacokinet. 2015. Published online 16 June 2015. DOI: 10.1007/s13318-015-0288-z.
   PubMedGoogle Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–1915.
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systemic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947–1955.
   PubMed Web of Science ®Google Scholar
• Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013;65:718–728.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445–1452.
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–222.
   PubMed Web of Science ®Google Scholar
• Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacytokinet. 2014;29:12–19.
   PubMed Web of Science ®Google Scholar
• Kooloos WM, Huizinga TW, Guchelaar HJ, et al. Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des. 2010;16:164–175.
   PubMed Web of Science ®Google Scholar
• Zhu H, Deng FY, Mo XB, et al. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharamcogenomics. 2014;15:551–566.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Meskó B, Poliska S, et al. Pharamacogenetics and pharmacogenomics in rheumatology. Immunol Res. 2013;56:325–333.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Yang S, Wei W, et al. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:531–538.
   PubMed Web of Science ®Google Scholar
• Kodidela S, Suresh CP, Dubashi B. Pharmacogenetics of methotrexate in acute lymphoblastic leukemia: why still at the bench level?. Eur J Clin Pharmacol. 2014;70:253–260.
   PubMed Web of Science ®Google Scholar
• Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics. 2013;14:305–314.
   PubMed Web of Science ®Google Scholar
• Ando Y, Shimada H, Matsumoto N, et al. Role of methotrexate polyglutamation and reduced fotale carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes. Drug Metab Pharmacytokinet. 2013;28:442–445.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther. 2009;34:355–361.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Greenstein N, Kremer J. Pharamcogenomic and metabolic biomarkers the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095–3103.
   PubMed Web of Science ®Google Scholar

• This study analyzed the contribution of MTX metabolites, folate polyglutamate levels and pharmacogenetic biomarkers in the folate pathway to the effects of MTX in patients with rheumatoid arthritis.

• Hughes LB, Danila MI, Bridges SL. Recent advances in personalizing rheumatoid arthritis therapy and management. Per Med. 2009;6:159–170.
   PubMed Web of Science ®Google Scholar
• Kung TN, Dennis J, Ma Y, et al. FRC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis. Arthritis Rheum. 2014;66:1111–1120.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Tazoe Y, Tsuboi S, et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacytokinet. 2013;28:164–168.
   PubMed Web of Science ®Google Scholar
• Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24:546–554.
   PubMed Web of Science ®Google Scholar

•• The authors investigated whether ABCB1 C3435T, RFC1 G80A, ATIC C347G and TYMS gene are predictive of MTX sensitivity and its adverse effects.

• Wessels JA, de Vries-Bouwstra JK, Hejimans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006;54:1087–1095.
   PubMed Web of Science ®Google Scholar

• This study analyzed the associations between MTX efficacy and toxicity and SNPs in genes coding for folate pathway enzymes in patients with early RA.

• Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007;127:1860–1867.
   PubMed Web of Science ®Google Scholar
• Bohanec-Grabar P, Leonardo-Garcia LJ, Inglada-Perez L, et al. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. Pharamcogenomics. 2012;13:1583–1594.
   PubMed Web of Science ®Google Scholar
• Lima A, Bernardes M, Sousa H, et al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharamocogenomics. 2014;15:807–820.
   PubMed Web of Science ®Google Scholar

• The results of this study suggest that SLC19A1 G80A genotyping may be a useful tool for clinicians to identify patients at higher risk for developing gastrointestinal toxicity related to MTX treatment.

• Lima A, Bernardes M, Azevedo R, et al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014;142:196–209.
   PubMed Web of Science ®Google Scholar

• Relatively recent study on SLC19A1 haplotype in MTX toxicity.

• Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not and what is promising. Curr Drug Metab. 2009;10:547–566.
   PubMed Web of Science ®Google Scholar
• Kato T, Hamada A, Mori S, et al. Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2012;27:192–199.
   PubMed Web of Science ®Google Scholar
• van der Straaten RJ, Wessels JA, de Vries-Bouwstra JK, et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics. 2007;8:141–150.
   PubMed Web of Science ®Google Scholar
• Rego-Pérez I, Fernández-Moreno M, Blanco FJ. Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Curr Genomics. 2008;9:381–393.
   PubMed Web of Science ®Google Scholar
• Stanislawska-Sachadyn A, Brown KS, Mitchell LE, et al. An insertion/deletion polymorphism of the dihydrofolate reductase (DHFR) gene is associated with serum and red blood cell folate concentrations in women. Hum Genet. 2008;123:289–295.
   PubMed Web of Science ®Google Scholar
• Devila-Fajardo CL, Swen JJ, Cabeza-Barrera J, et al. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics. 2013;14:63–73.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics. 2011;12:1449–1463.
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Pawlik A, Safranow K, et al. 677C>T and 1298A>C MTHRF polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics. 2007;8:1551–1559.
   PubMed Web of Science ®Google Scholar
• Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharamacogenetics. 2002;12:183–190.
   PubMedGoogle Scholar

• The authors have shown that polymorphisms within the MTHFR gene are associated with both the efficacy and toxicity of MTX in rheumatoid arthritis patients.

• Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genom. 2007;17:383–390.
   PubMed Web of Science ®Google Scholar
• Palomino-Morales R1, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther. 2010;12:R71.
   PubMed Web of Science ®Google Scholar
• Soukup T, Dosedel M, Pavek P, et al. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients. Rheumatol Int. 2015;35:1149–1161.
   PubMed Web of Science ®Google Scholar
• Lima A, Seabra V, Bernardes M, et al. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in Portuguese rheumatoid arthritis patients. PLOS One. 2014;9:e108165.
   PubMed Web of Science ®Google Scholar
• Horie N, Aiba H, Oguro K, et al. Functional analysis and DMNA polymorphism of the tandemly repeated sequences in the 5ʹ-terminal regulatory region of the human gene for tymidylate synthase. Cell Struc Funct. 1995;20:191–197.
   PubMed Web of Science ®Google Scholar
• Jekic B, Lukovic L, Bunjevacki V, et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol. 2013;69:377–383.
   PubMed Web of Science ®Google Scholar
• Sharma S, Das M, Mukar A, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics. 2009;19:823–828.
   PubMedGoogle Scholar
• Pawlik A, Herczynska M, Kurzawski M, et al. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics. 2009;10:303–309.
   PubMed Web of Science ®Google Scholar
• O’Doherty C, Schnabl M, Spargo L, et al. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics. 2012;13:1427–1434.
   PubMed Web of Science ®Google Scholar
• Wiese MD, Schnabl M, O’Doherty C, et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14:R163.
   PubMed Web of Science ®Google Scholar
• Bohanec-Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol. 2008;64:871–876.
   PubMed Web of Science ®Google Scholar

• The results of this study suggest that genetic variability in leflunomide-metabolizing enzymes influences leflunomide metabolite concentrations that are associated with the treatment response.

• Bohanec-Grabar P, Grabnar I, Rozman B, et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos. 2009;37:2061–2068.
   PubMed Web of Science ®Google Scholar
• Dziedziejko V, Kurzawski M, Safranow K, et al. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics. 2011;12:41–47.
   PubMed Web of Science ®Google Scholar
• Dziedziejko V, Kurzawski M, Safranow K, et al. Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide. Eur J Clin Pharmacol. 2012;68:371–377.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Ohshima N, Yanagida T, et al. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol. 2002;2:631–640.
   PubMed Web of Science ®Google Scholar
• Imai F, Suzuki T, Ishibashi T, et al. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J Rheumatol. 1994;21:612–615.
   PubMed Web of Science ®Google Scholar
• Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163–1174.
   PubMed Web of Science ®Google Scholar
• Akahoshi T, Namai R, Sekiyama N, et al. Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J Leukoc Biol. 1997;62:817–826.
   PubMed Web of Science ®Google Scholar
• Wiese MD, Alotaibi N, O’Doherty C, et al. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics J. 2014;14:350–355.
   PubMed Web of Science ®Google Scholar
• Wadelius M, Stjernberg E, Wiholm BE, et al. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics. 2000;10:35–41.
   PubMedGoogle Scholar
• Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol. 2002;29:2492–2499.
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–916.
   PubMed Web of Science ®Google Scholar
• Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118:3537–3545.
   PubMed Web of Science ®Google Scholar
• Wada T, Son Y, Ozaki Y, et al. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis. Mod Rheumatol. 2012;22:824–830.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:353–363.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473–488.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41:1258–1265.
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–1528.
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Sierakowski S, Domyslawska I, et al. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp. 2004;52:36–42.
   PubMed Web of Science ®Google Scholar
• Ulfgren AK, Andersson U, Engström M, et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. 2000;43:2391–2396.
   PubMed Web of Science ®Google Scholar
• Kubota A, Hasegawa K, Suguro T, et al. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol. 2004;31:426–435.
   PubMed Web of Science ®Google Scholar
• Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum. 2004;50:3831–3843.
   PubMed Web of Science ®Google Scholar
• Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:795–800.
   PubMed Web of Science ®Google Scholar
• Verweij CL. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. Ann Rheum Dis. 1999;58:120–126.
   Google Scholar
• de Vries N, Tak PP. The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology (Oxford). 2005;44:705–707.
   PubMed Web of Science ®Google Scholar
• Fonseca JE, Carvalho T, Cruz M, et al. Polymorphism at position −308 of the tumour necrosis factor alpha gene and rheumatoid arthritis Pharmacogenetics. Ann Rheum Dis. 2005;64:793–794.
   PubMed Web of Science ®Google Scholar
• Elahi MM, Asotra K, Matata BM, et al. Tumor necrosis factor alpha −308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009;1792:163–172.
   PubMed Web of Science ®Google Scholar
• Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol. 2001;62:1191–1199.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Fanning GC, Chapel HM, et al. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol. 1997;159:6236–6241.
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67:478–484.
   PubMed Web of Science ®Google Scholar
• Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008;17:3532–3538.
   PubMed Web of Science ®Google Scholar

• Large population in single polymorphism study.

• Guis S, Balandraud N, Bouvenot J, et al. Influence of −308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007;57:1426–1430.
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmuller U, Moller B, et al. The −308 tumour necrosis factor-{alpha} gene polymorphism predicts therapeutic response to TNF{alpha}-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46:93–96.
   PubMed Web of Science ®Google Scholar
• Cuchacovich M, Ferreira L, Aliste M, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of –308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2004;33:228–232.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int. 2007;27:383–386.
   PubMed Web of Science ®Google Scholar
• Padyukov L, Lampa J, Heimburger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003;62:526–529.
   PubMed Web of Science ®Google Scholar
• Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position –308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003;48:1849–1852.
   PubMed Web of Science ®Google Scholar
• Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis. 2006;65:342–347.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, et al. TNFA −308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis. 2011;216:125–130.
   PubMed Web of Science ®Google Scholar
• Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position –857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:547–552.
   PubMed Web of Science ®Google Scholar
• van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(−kappa)B transcription factors. Hum Mol Genet. 2002;11:1281–1289.
   PubMed Web of Science ®Google Scholar
• Hohjoh H, Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun. 2001;2:105–109.
   PubMed Web of Science ®Google Scholar
• Swierkot J, Bogunia-Kubik K, Nowak B, et al. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82:94–99.
   PubMed Web of Science ®Google Scholar
• Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004;50:2750–2756.
   PubMed Web of Science ®Google Scholar
• Ongaro A, De Mattei M, Pellati A, et al. Can tumor necrosis factor receptor II gene 676T > G polymorphism predict the response grading to anti-TNF-alpha therapy in rheumatoid arthritis?. Rheumatol Int. 2008;28:901–908.
   PubMed Web of Science ®Google Scholar
• Fabris M, Di PE, D’Elia A, et al. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol. 2002;29:29–33.
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A, Georgiou I, Voulgari PV, et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients’ response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford). 2007;46:1034–1035.
   PubMed Web of Science ®Google Scholar
• Toonen EJ, Coenen MJ, Kievit W, et al. The tumour necrosis factor receptor superfamily member 1b 676TNG polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis. 2008;67:1174–1177.
   PubMed Web of Science ®Google Scholar
• Avil-Pedretti G, Tornero J, Fernandez-Nebro A, et al. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One. 2015;10:e0122088.
   Google Scholar

• Recent study, and new genes identified associated with the response to anti-TNF treatment.

• Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1547–1552.
   PubMed Web of Science ®Google Scholar
• Montes A, Perez-Pampin E, Narvaez J, et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:238–245.
   PubMed Web of Science ®Google Scholar
• Mathews RJ, Robinson JI, Battellino M, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis. 2014;73:1202–1210.
   PubMed Web of Science ®Google Scholar
• Sode J, Vogel U, Bank S, et al. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. PLoS One. 2014;9:e100361.
   Web of Science ®Google Scholar
• Potter C, Cordell HJ, Barton A, et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis. 2010;69:1315–1320.
   PubMed Web of Science ®Google Scholar
• Nishimoto T, Seta N, Anan R, et al. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32:211–217.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784–788.
   PubMed Web of Science ®Google Scholar
• Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–234.
   PubMed Web of Science ®Google Scholar
• Lo SF, Huang CM, Lin HC, et al. Cytokine (IL-6) and chemokine (IL-8) gene polymorphisms among rheumatoid arthritis patients in Taiwan. Clin Exp Rheumatol. 2008;26:632–637.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Choi SJ, et al. The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res. 2012;61:665–671.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin‐6 (IL‐6) gene on IL‐6 transcription and plasma IL‐6 levels, and an association with systemic‐onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–1376.
   PubMed Web of Science ®Google Scholar

• Important meta-analysis.

• Hulkkonen J, Pertovaara M, Antonen J, et al. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL-6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford). 2001;40:656–661.
   PubMed Web of Science ®Google Scholar
• Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6 174 G/C polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22:2219–2220.
   PubMed Web of Science ®Google Scholar
• Davila-Fajardo CL, Marquez A, Pascual-Salcedo D, et al. Confirmation of −174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics. 2014;24:1–5.
   PubMed Web of Science ®Google Scholar
• Jancic I, Arsenovic-Ranin N, Sefik-Bukilica M, et al. 174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int. 2013;33:1481–1486.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. Functional FCGR3A 158 V/F and IL-6 −174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2014;34:1409–1415.
   PubMed Web of Science ®Google Scholar
• Ceccarelli F, Perricone C, Fabris M, et al. Transforming growth factor β 869C/T and interleukin 6–174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R111.
   Google Scholar
• Hassan B, Maxwell JR, Hyrich KL, et al. Genotype at the sIL-6R A358 C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford). 2010;49:43–47.
   PubMed Web of Science ®Google Scholar
• Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69–74.
   PubMed Web of Science ®Google Scholar
• Ogata A, Amano K, Dobashi H, et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol. 2015;42:799–809.
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Östör A. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2015;14:429–437.
   PubMed Web of Science ®Google Scholar
• Narváez J, Díaz-Torné C, Magallares B, et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. PLoS One. 2015;10:e0123392.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40:768–780.
   PubMed Web of Science ®Google Scholar
• Wang J, Bansal AT, Martin M, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. 2013;13:235–241.
   PubMed Web of Science ®Google Scholar

•• Large population examined in GWAS study.

• Enevold C, Baslund B, Linde L, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:401–405.
   PubMed Web of Science ®Google Scholar
• Fabris M, Quartuccio L, Lombardi S, et al. Study on the possible role of the −174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo. 2010;62:253–258.
   PubMedGoogle Scholar
• Fabris M, Quartuccio L, Lombardi S, et al. The CC homozygosis of the −174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev. 2012;11:315–320.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115–123.
   PubMed Web of Science ®Google Scholar
• Daïen CI, Fabre S, Rittore C, et al. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine. 2012;79:471–475.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Pontarini E, et al. The 158VV Fc gamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis. 2014;73:716–721.
   PubMed Web of Science ®Google Scholar
• Kastbom A, Coster L, Arlestig L, et al. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open. 2012;2:e001524.
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2012;71:875–877.
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Rouanet S, Combe B, et al. Association between −871C/;T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford). 2013;52:636–641.
   PubMed Web of Science ®Google Scholar
• Fabris M, Quartuccio L, Saracco M, et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum. 2009;60:1678.
   Google Scholar
• Fabris M, Quartuccio L, Vital E, et al. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum. 2013;65:88–97.
   PubMed Web of Science ®Google Scholar
• Talotta R, Bagnato GL, Atzeni F, et al. Polymorphic alleles in exon 1 of the CTLA4 gene do not predict the response to abatacept. Clin Exp Rheumatol. 2013;31:813.
   PubMed Web of Science ®Google Scholar
• Camp NJ, Cox A, di Giovine FS, et al. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun. 2005;6:467–471.
   PubMed Web of Science ®Google Scholar
• Lee YH, Ji JD, Bae SC, et al. Associations between tumor necrosis factor-a (TNF-a) −308 and −238 G/A polymorphisms and shared epitope status and responsiveness to TNF-a blockers in rheumatoid arthritis: a meta-analysis update. J Rheumatol. 2010;37:740–746.
   PubMed Web of Science ®Google Scholar
• Pavy S, Toone EJM, Miceli-Richard C, et al. Tumour necrosis factor a-308G? A polymorphism is not associated with response to TNF-a blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2010;69:1022–1028.
   PubMed Web of Science ®Google Scholar

• Important meta-analysis.